振東製藥(300158.SZ):第三季度報告披露時間延期至10月30日
格隆匯 10 月 26日丨振東製藥(300158.SZ)公佈,公司原定於2020年10月27日在深圳證券交易所創業板指定信息披露平台上披露公司2020年第三季度報告。由於2020年第三季度報告相關編制工作預計完成時間晚於預期,導致2020年第三季度報告不能如期披露。本着審慎原則及對廣大投資者負責的態度,同時為確保公司信息披露內容的準確和完整性,經公司慎重研究,公司《2020年第三季度報告》披露時間延期至2020年10月30日。公司董事會對此次調整2020年第三季度報告披露時間給廣大投資者帶來的不便致以最誠摯的歉意,敬請廣大投資者諒解。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.